Samsung Biologics’ Plant 4 facility (courtesy Samsung)
April 24, 2024 10:55 AM EDTUpdated April 29, 04:42 AM
Manufacturing

Sam­sung Bio’s bet on Plant 4 con­tin­ues to pay off with first-quar­ter earn­ings growth

Anna Brown

News Reporter

Sam­sung Bi­o­log­ics’ Plant 4 re­mains a worth­while $2 bil­lion in­vest­ment.

The CD­MO said that the fa­cil­i­ty was key in its first-quar­ter gains and will con­tin­ue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times